JY
ORGS

Jeff Yass’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Jeff Yass’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,430
Closed -$170K – 14094
2021
Q3 		$170K Sell
3,430
-1,360
-28% -$68.3K ﹤0.01% 11671
2021
Q2 		$243K Buy
+4,790
New +$241K ﹤0.01% 11203

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $1.5B AUM 26.39% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's ORGS Position: Q4 2022 in Review

Jeff Yass sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2022, closing a stake of 2,927 shares — an estimated $42K sold.

Jeff Yass first reported a position in ORGS in Q3 2019 and held it in 3 quarters. The position peaked at $58K in Q3 2019. 20 funds tracked by Wall St. Rank hold ORGS as of Q4 2022.

  • Jeff Yass reported no remaining Orgenesis Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Jeff Yass sold 2,927 Orgenesis Inc. Common Stock shares in Q4 2022, an estimated $42K.
  • Jeff Yass first reported a position in Orgenesis Inc. Common Stock in Q3 2019 and held it in 3 quarters.
  • Jeff Yass's Orgenesis Inc. Common Stock position peaked at $58K in Q3 2019.
  • 20 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.